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Monoclonal antibodies (MAbs) have the potential for diagnosis and therapy of cancer. 
5G6.4 is a MAb of the IgG2a class which was produced by immunization of BALB/c mice 
with human ovarian carcinoma (Ov Ca) cells. To further characterize 5G6.4, its effect on 
cell growth was tested using a human Ov Ca cell line established in our laboratory. A 
clonogenic assay was set up in 48-well plates in a double agar system. The cells were 
plated and 5G6.4 was added at different concentrations. Control plates consisted of ceils 
with media without MAb. Negative control plates were also prepared using the same 
concentrations of an isotype-matched antimelanoma MAb, 225.28s. Colony formation (CF) 
was reduced to 50% or less of control with increasing amounts of 5G6.4 up to 50 pg/ml. 
Although CF was still depressed at concentrations above 50 pg/ml, the inhibition did not 
follow a directly proportional line; instead, it followed a bell-shaped curve. Plates with 
the control MAb, 225.28s did not show this response. Similar results were obtained with 
cells from malignant Ov Ca ascites in the same clonogenic assay. Our study suggests that 
in the evaluation of the in vitro effect of MAb on growth, the concentration of MAb is 
crucial and may not show a linear response and that 506.4 may have a direct therapeutic 
effect by blocking the growth of Ov Ca cells. 566.4 is presently under study for therapy 
iII an aniIna1 model. 0 1987 Academic Press, Inc. 
INTRODUCTION 
Monoclonal antibodies (MAbs) have the potential for use in therapy of cancers 
[I ,2] and have been used in some clinical trials in humans [3-81. The results 
have been varied, and in some cases interaction of the host’s immune system 
has appeared to be important in positive responses [3,9]. Studies have concentrated 
on complement activation or cell cooperation, such as antibody-dependent cell- 
mediated cytotoxicity (ADCC; [IO-121). Yet another group of monoclonal antibodies 
is capable of directly inhibiting the growth of cells [13,14]. 
We have begun evaluation of a monoclonal antibody, 566.4, reactive with 
human ovarian carcinoma (Ov Ca) cells. Unlike some MAbs to leukemia which 
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cause modulation or loss of antigen expression [15], the 5G6.Cdefined antigen 
does not appear to modulate (Wahl and Liebert, unpublished). Radioiodinated 
566.4 localizes well in subcutaneous human ovarian tumors in nude mice, with 
tumor: blood ratios of 5 : 1 to 10: 1 [ 16,171. Although 5G6.4 does bind to some 
normal human tissues (skin and kidney) [16], its high expression on Ov Ca cells 
and good localization in human tumor-bearing nude mice suggest promise as an 
immunolocating or immunotherapeutic agent. In this study, we demonstrate antigen 
expression on Ov Ca cells by flow cytometry and radiolabeled antibody binding. 
To further evaluate the usefulness of 566.4 for immunotherapy, we tested its 
ability to block growth of these cells using an in vitro colony formation assay. 
MATERIALS AND METHODS 
Cell lines. The methods for initiation and maintenance of the cell line used in 
this study have been previously described [18]. Briefly, the cell line (MI OV) 
was maintained in RPM1 1640 media supplemented with 10% heat-inactivated 
fetal bovine serum, 1% nonessential amino acids, 100 IU penicillin/ml, 100 pg 
streptomycin/ml, 2 mM glutamine. The cells were grown in T-25 tissue culture 
flasks and kept in a 37°C incubator at a 5% CO2 atmosphere. 
Collection of cells. Malignant effusion from a patient of documented recurrent 
carcinoma was used to retest the assay with a fresh tumor. Three liters of ascitic 
fluid was centrifuged (1000 rpm for ten min). The cells (TA OV) were then 
resuspended in RPM1 and an aliquot was counted in a hemocytometer with 
trypan blue to identify the viable cells. The cells were resuspended into an 
adequate volume of RPM1 in order to get the predetermined cell density needed 
for the clonogenic assay. 
Monoclonal antibodies. 566.4 is an IgG2a murine monoclonal antibody prepared 
by immunizing BALB/c mice with HTB77, a human ovarian carcinoma cell line. 
It is directed against an epithelial tumor-associated antigen, found on the basal 
layer of various epithelia, proximal tubules of the kidney, ovarian tumors and 
several other types of tumors [16]. 225.28s is a monoclonal antibody reactive 
with a high-molecular-weight chondroitin sulfate antigen found in melanoma cells 
[19]. It is of the IgG2a subclass. UPC-10 is a murine myeloma IgG2a protein. 
Purified UPC-10 was purchased from Litton Bionetics (Rockville, MD). Antibodies 
were purified by affinity chromatography on staphylococcal protein A columns 
[20]. Purified antibodies were sterilized by filtration through a 0.22 pm filter 
(Millipore, Bedford, MA) and were dialyzed against RPM1 without serum overnight 
at 4°C under sterile conditions. The protein concentration was checked using 
the Bradford protein assay [21] immediately before use. 
Flow cytometry. Washed tissue-cultured cells were incubated with 506.4 at 
20 pg/ml in 2% bovine serum albumin in phosphate-buffered saline (0.01 M 
phosphate, pH 7.2, 0.14 M NaCl; BSA/PBS). Cells incubated in BSA/PBS 
without antibody were used as a control. The cells were incubated for 1 hr on 
ice and washed three times with BSA/PBS. Then the cells were resuspended in 
1 ml of fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Cappel, 
Cochranville, PA) diluted l/100 in BSA/PBS and the mixture was incubated for 
1 hr on ice. The cells were washed three times with BSA/PBS and resuspended 
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FIG. 1. Flow cytometry of MI Ov Ca cells without (no shading) or with (shaded) X36.4. 
in 1 ml BSA/PBS. The fluorescence of cells was observed by fluorescence 
microscopy and analyzed using an Epics C flow cytometer (Coulter Diagnostics, 
Hialeah, FL). 
lo&nation. Antibodies were radiolabeled with lz51 using “Iodogen” as previously 
described [22]. Cell-binding assays were performed as previously described [23]. 
Soft agar clonogenic assay. An agar underlayer of 0.5% molten Bacto-agar 
(Difco Laboratories, Detroit, MI) was poured over the bottom of 48-well plates. 
After the agar solidified, the tumor cell-plating layer was poured over the top. 
Tumor cell-plating density was 2 x 10’ cells/well, suspended in 0.3% molten 
Bacto-agar. The culture media added to both agar layers was RPM1 on the bottom 
layer and the same media in which the cell lines grow on the top layer. After 
solidification of the agar the plates were incubated at 37°C with 5% CO2 overnight. 
Twenty-four hours later, different concentrations of MAb diluted in RPM1 were 
added to the top layer. The same volume of RPMI, without any antibody, was 
used as control. The cells were incubated again, and after 7-14 days, colonies 
were visible. Colonies were defined as aggregates of greater than 30 cells. Colony 
formation in control plates were compared to the number of colonies growing 
in the cultures with the different concentrations of MAb overlayers. Results of 
colony formation are given as percentage of control. All experiments were done 
in triplicate and the person reading the plates for colonies did not know which 
plates had antibody overlay nor their concentrations. MI OV cell line experiments 
were repeated three times and the fresh tumor (TA OV) experiment was performed 
once. 
RESULTS 
The reaction of 566.4 with MI Ca Ov cells is shown in Fig. 1 by flow cytometry. 
Cells incubated with an equal concentration of an isotype-matched control antibody 
(UPC-lo) showed fluorescence intensity similar to cells incubated without antibody 
(data not shown). In the beginning of these experiments, 225.28s was used as a 
control antibody because the high-molecular-weight chondroitin sulfate antigen 
was thought not to be expressed by Ov Ca cells. In the course of these experiments, 
the 225.28s was shown to bind to Ov Ca cells by immunofluorescence microscopy. 
In a binding assay using radioiodinated antibodies, Ov Ca cells bound 3.5 times 
more 566.4 than 225.28s (data not shown). 225.28s has been reported to have 
an in vitro effect on melanoma cell growth due to ADCC [121. In our hands, its 
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FIG. 2. Colony formation inhibition of MI Ov Ca cells in the presence of 5G6.4 (solid) or 225.28s 
(shaded). 225.28s was not tested at 250 fig/ml. 
in vitro effect on Ov Ca colony formation was inconsistent possibly due to a 
low level of antigen expression. 
Figures 2 and 3 show the percentage of colony formation of the two different 
tumor cells used in relation to the different concentrations of 5G6.4 and 225.28s. 
The curves for both cell populations show a bell-shaped distribution for 566.4. 
The optimum concentration for best inhibition of tumor colony formation by 
566.4 was 50 pg/ml for both cell populations. For MI OV colony formation was 
inhibited to 40-55% of control and for the malignant effusion it was 11% of 
control (P < 0.05 compared to control using Student’s t test). 
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FIG. 3. Colony formation inhibition of TA Ov Ca cells in the presence of MAb X6.4 (solid) or 
225.28s (shaded). 225.28s was not tested at 12.5 Fg/ml. 
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DISCUSSION 
We report here the ability of a MAb, 566.4, to block the growth of human 
Ov Ca cells in a tumor colony-forming assay in a nondose-related fashion. These 
results suggest that 5G6.4 may have potential immunotherapeutic usefulness but 
also indicate that the dose of antibody used for immunotherapy may be important. 
These results may be especially significant because of the nature of the colony- 
formation assay used. Growth of colonies measured in this assay is reportedly 
due to cells responsible for continued tumor growth and metastasis (“stem cells”) 
[241. 
Our results differ from those reported for several other MAbs capable of in 
vitro growth suppression. A MAb binding to transferrin receptor was previously 
shown to block cell growth in vitro, but in a dose-dependent fashion [13,25]. 
Prolonged exposure of melanoma cells to MAb R-24, an anti-GD3 ganglioside 
antibody, was shown to arrest cell growth, again in a dose-dependent fashion 
[143. While the first assay looks at the growth inhibition of the whole malignant 
cell population, the second assay (used in our study) focuses on the growth 
inhibition of stem cells, which hypothetically are responsible for totipotential 
and continuous tumor growth. 
The mechanism of growth inhibition by 566.4 remains to be determined. The 
unusual response to 566.4 (i.e., inhibition at 25 and 50 pg/ml, lost at lower or 
higher concentrations of antibody) suggests some biological feedback. R-24, the 
anti-ganglioside GD3 MAb, appears to act through changes in membrane attachment 
sites [ 141. Antitransferrin receptor may block uptake of essential nutrients [ 13,251. 
Ov Ca cells have been reported to have growth factor receptors and to produce 
growth factors [26], both of which could act as targets for antibodies capable of 
growth inhibition. However, the 5G6.4 antigen does not resemble growth factors 
or receptors described previously (13,25,26). Further, the antigen reactive with 
566.4 appears to be a glycoprotein rather than a ganglioside or glycolipid, so 
the activity does not appear to be similar to R-24 (Wahl et al., unpublished). 
These results suggest that MAb 5G6.4 may have a direct immunotherapeutic 
effect by blocking the growth of Ov Ca “stem cells.” We are continuing the 
investigation of this activity and testing this MAb in viva in a nude mouse model. 
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